Last update: Nov. 3, 2018
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
It is a derivative of nitrofuran with antiprotozoal and antibacterial activity.
Indicated in the treatment of giardiasis and cholera. In other types of gastroenteritis antibiotic treatment is not usually indicated. It is also used in the treatment of peptic ulcer caused by Helicobacter pylori.
Oral administration 4 times a day for 2 to 5 days or a maximum of 7 to 10 days in Giardia lamblia infestation.
Since the last update we have not found published data on its excretion in breastmilk.
Little is known of this drug’s pharmacokinetic data in humans.
There is controversy about its oral bioavailability. Although it is believed that it exerts its effect locally in the intestine without being absorbed (Kumar 1995, Valadez 1989), there are authors who have recorded 65% absorption (Calafatti 2001 -> White 1989).
Side effects are rare and mild, usually nausea/vomiting (Altamirano 1989). Although its properties as a monoamine oxidase inhibitor (MAOI) are known, no adverse neurological reactions due to the isolated use of this drug have been recorded (Karamanakos 2008, Bettinger 1968).
Its use is authorized in infants from the one month old (Induquímica 2018, RxList 2004, Drugs.com 1995).
Do not use if there is a history of glucose-6-phosphate dehydrogenase deficiency, in order to avoid risk of hemolysis (Induquímica 2018, RxList 2004, Drugs.com 1995).
Some authors discourage its use during breastfeeding (Mahadevan 2006). Other authors and the manufacturer only advise against its use in mothers with infants younger than one month (Induquímica 2018, Drugs.com 1995).
One mother told us in 2018 that after taking 4 doses of 100 mg of furazolidone along with famotidine, over 24 hours she noticed more drowsiness than usual in her 13-week-old breastfeeding daughter, returning to normal within 48 hours of stopping the medication.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM